Adam Gehring received his Ph.D. at Case Western Reserve University in Cleveland, Ohio. His training included a Postdoctoral Fellowship in the Institute of Hepatology at University College London and a position of Senior Research Fellow, and subsequently Assistant Principal Investigator, at the Singapore Institute for Clinical Sciences with Antonio Bertoletti. Dr. Gehring moved to Saint Louis University as an Assistant Professor in March 2013 before taking a position at the Toronto Center for Liver Disease in February 2016. Dr. Gehring is currently the Scientific Director of the Schwartz Reisman Liver Research Centre, Senior Scientist at the Toronto Center for Liver Disease and Associate Professor in the Department of Immunology at the University of Toronto. He runs a translational, human HBV immunology research lab focused on liver pathogenesis and immunotherapy. His primary interest lies in defining the mechanisms driving liver inflammation during HBV-related hepatitis using functional and transcriptomic approaches in liver biopsies collected as part of Phase 1 – 3 clinical trials. He runs an immune profiling lab for the Toronto Centre for Liver Disease to process and analyze immune responses in Phase 1 - 3 clinical studies for novel therapeutic agents targeting HBV.